LTR Pharma Limited (AU:LTP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LTR Pharma Limited’s new nasal spray SPONTAN® has shown promising results in a pivotal clinical study for erectile dysfunction treatment, absorbing 470% faster than oral tablets and offering a 155.6% higher peak concentration at half the dose. With a comparable bioavailability and safety profile, SPONTAN® is poised to be a market disruptor by providing patients with a more spontaneous and convenient option. The study’s outcomes are expected to strengthen LTR Pharma’s global commercialization and regulatory strategies.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.